HOME
ANZ BCTG PROFILE
NEWS AND MEDIA RELEASES
CLINICAL TRIALS
Prevention
Early Breast Cancer
Advanced
ANNUAL PARTICIPANTS' SCIENTIFIC MEETING
CONSUMER ADVISORY PANEL
BREAST CANCER INSTITUTE OF AUSTRALIA
POSITIONS VACANT
USEFUL LINKS
BECOME A MEMBER
CONTACT INFORMATION
SEARCH
LOGIN
Username :
Password :
Forgot Your Password?
Printer Friendly
Advanced disease
ANZ 0802 / CIRG / TRIO 012 : TRIO-012
A multicentre, multinational, randomised, double-blind, phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.
ANZ 1001 : SORBET - Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen
A single arm phase II study of the efficacy of tamoxifen in triple negative (oestrogen receptor alpha negative, progesterone receptor negative, HER-2 negative) but oestrogen receptor beta positive metastatic breast cancer.
ANZ BCTG receives research infrastructure funding from the Cancer Institute NSW
and the Australian Government through Cancer Australia
Copyright ©
2010
Australian New Zealand Breast Cancer Trials Group Limited. All Rights Reserved.
Copyright & Disclaimer
|
Privacy Policy